

# Entrepreneurs in Residence:

Not Just for VCs



## The Region: Central Maryland

#### **Unrivaled Research Assets**

**•** 59 Federal Laboratories, Centers, and Institutes

Annual Maryland R&D Investment

♣ Federal: \$12 billion

JHU/USM: \$3.5 billion





# An Innovation Intermediary

# Align local technologies, assets and resources to advance innovation

**Regionally-oriented** 

Private-public partnership

501(c)(3) nonprofit

Market-driven

Private sector-led


**Technology** Focus **E-Health Therapeutics Mobile Health Medical Devices Healthcare Services Electronic Medical Records BioHealth Cyber Security Health Informatics Diagnostics** 



# Partners and Sponsors



#### **BHI Commercialization Model**




## **Innovation Paradigm Shift**

Proof of CONCEPT (Technological Feasibility) Laboratory Push

"It Works!"



#### PROOF OF COMMERCIAL RELEVANCE (Market Pull) "It Works To Solve A Problem" "I'll Buy It"



What is an Entrepreneur in Residence?

### An active partner with research institutions

Source Fund Grow Businesses.

Served in a business development role Experience in Seed Venture Capital Firm Senior Management in a life sciences Startup

**EIR Criteria** 

## Our Entrepreneur in Residence: Todd Chappell



## Scientific 13 Years

- Financial / Venture Capital 4 Years
- Entrepreneurial Management
   13 Years

## **Experience**

#### **BioHealth Innovation, Inc. EIR Program**



"I thought that the BHI EIR experience would lead me to my next startup... but instead I now feel like a kid in a scientific candy store with the unlimited opportunities of the EIR program becoming its own interesting startup."

## **Todd Chappell**

Our Entrepreneur in Residence: Todd Chappell

**Evaluate** 

+ 30 NIH Postdocs and Interns

Identify
+ Drugs





- Diagnostics
- Therapeutics
- Medical Devices



Transfer /

**Startup** 

#### **NIH/OTT Partnership Intermediary Agreement**




"The NIH OTT/ BHI EIR program helps our 150 technology transfer professionals gain access to real-time needs of industry, the market, and the investment community."

## Mark Rohrbaugh

Director of the NIH Office of Technology Transfer

## NIH/OTT: First Year Outcomes



Advanced Personalized Diagnostics, LLC

symcat Ahead Research, Inc.

) Mimetas

Perceptive Navigation, LLC

Advanced Personalized Diagnostics, LLC

#### Personalized Cancer Care



Offers chemosensitivity profiling services to provide personalized treatment plans

Dr. Cuttitta (NCI) and Dr. Fang (NIH)



symcat Ahead Research, Inc.


#### Personalized Diagnostics

Web/Mobile application that matches patients to high quality healthcare providers

#### Craig Monsen

÷







÷

Organ-on-a-Chip solutions as an early screening model to predict toxic side effects and drug efficacy

#### Paul Vulto and Jos Joore




#### Perceptive Navigation, LLC

#### Medical Device

Develops medical devices related to image-guided, minimally-invasive markets

#### Dr. Ted Abraham






## **Potential Future Expansion**


## **BHI Global Expansion**

- North America
- Netherlands
- **Germany**
- + China
- Korea
- Portugal

## Innovation Capital Valley of Death



## Maryland Statistics: Venture Capital Dollars Invested



PricewaterhouseCoopers Moneytree



Accelerator

Federal

#### **Central Maryland Innovation Capital Map**

#### **Capital Sources by Investment Stage**

Pre-Proof of Concept \$25K - \$1.5M <sub>(over 5 years)</sub>	Translational Research / Proof of Concept \$15K - \$750K (over 3 years)	Proof of Commercial Relevance / Pre-Seed \$3K - \$500K	Seed / Start-Up \$50K - \$1.5M	<b>Early Stage</b> \$250K - \$2M	Later Stage \$2M+
<ul> <li>NIH R01</li> <li>NIH R03</li> <li>NIH R21</li> <li>Maryland Innovation Initiative (MII) (Managed by TEDCO)</li> </ul>	<ul> <li>NCATS Cures Acceleration Network (CAN)</li> <li>SBIR/STTR Grant Phase I</li> <li>Maryland Stem Cell Research Fund (MSCRF)</li> <li>TEDCO Technology Validation Program</li> <li>JHU-Coulter Translational Research Partnership</li> </ul>	<ul> <li>Maryland Industrial Partnerships (MIPS @ UMD)</li> <li>Maryland Biotechnology Center's Translational Research Award</li> <li>TEDCO Technology Commercialization Fund</li> <li>MII Phase 2 Grant</li> <li>MII Phase 3 Grant</li> <li>BHI SBIR/STTR Commercial Relevance Program (CRP)</li> </ul>	<ul> <li>Dingman Center Angels (UMD)</li> <li>Propel Baltimore Fund</li> <li>SBIR / STTR Phase II</li> <li>BHI Central Maryland Angel Fund</li> <li>BHI Commercial Relevance Fund (CRF)</li> </ul>	<ul> <li>Maryland Health Care P Development Corporation</li> <li>Invest Maryland: Maryland Venture Fund</li> <li>Maryland Biotechnology Center's Biotechnology Commercialization Awa</li> <li>Abell Venture Fund</li> <li>MMG Ventures LP</li> <li>TDF</li> </ul>	on Authority and ABS Capital Partners Greenspring Associates
Associations Association of University Resource Parks (AURP) Association of University Technology Managers (AUTM) Licensing Executive Society (LES) Funding Type Key			<ul> <li>Angel Capital Association (ACA)</li> </ul>	Mid-Atlantic Venture Association (MAVA	Association (NVCA)
Academic Associations ★ BioHealth Innovation, Inc.			State of Maryland     Maryland Biotechnology     Investor Tax Credit		

Montgomery County Biotechnology Investor Tax Credit

3/6/2013

- Innovation-based Economic Development (IBED)
- - Venture Capital



## **Innovation Capital Programs**

### **SBIR/STTR Assistance Program**


Help companies prepare high-quality SBIR/STTR grant proposals.

## **BHI Angel Fund**

Bridge the gap between pre-seed investments and institutional venture capital.

### **BHI Commercial Relevance Investment Fund**

Pre-seed and early-stage, equity-based innovation capital fund to help grow companies



## New BHI Health IT Accelerator


An intensive 16-week program for top-recruited companies and entrepreneurs

Provides a network of experienced mentors in:

- Business
- Marketing
- **Product Development**

No HIT accelerators currently in Maryland

## **Public Private Partnerships**



# Richard A. Bendis President & CEO



Cell: (215) 594-3333 Office: (301) 637-6439 Email: rbendis@bendisig.com Session URL: http://schedule.sxsw.com/2013/events/event\_IAP2203

"The BHI EIR program represents a significant paradigm shift in the way NIH hopes to advance commercially relevant science."